Published in Nature Medicine · View the paper (DOI)
A new study finds that GLP-1 drugs tirzepatide and semaglutide reduce the risk of heart attack, stroke, and death from any cause in patients with type 2 diabetes. Both medications provide strong cardioprotective effects and may be integrated into clinical cardiovascular practice.
Coverage from 2 institutions